Close menu




December 22nd, 2020 | 09:26 CET

BYD, Saturn Oil & Gas, JinkoSolar - The path is clear!

  • Investments
Photo credits: Saturn Oil & Gas Inc.

The oil price has been strong in recent weeks. If it goes according to the major investment houses, the positive trend will continue. Thus, the experts of Citigroup assume that the global oil demand will reach the pre-Corona level by the end of 2021. Currently, a takeover battle is taking place in the industry which offers companies the opportunity to completely reposition themselves and emerge from the crisis even stronger.

time to read: 2 minutes | Author: Stefan Feulner
ISIN: CA80412L1076 , CNE100000296 , US47759T1007

Table of contents:


    2020 - The year of opportunities

    Quiet has fallen around the most favourable oil producer in Canada in the 2019 production year. While Saturn Oil & Gas had total costs of USD 12 per barrel on the clock, spending by oil giants such as Shell, Exxon Mobile and BP was above the USD 30 mark. To maintain this level, CEO John Jeffrey indicated that it was easier and cheaper to look for suitable acquisitions than to explore oil himself. In addition to identifying suitable takeover targets, various due diligence reviews have already been underway for months, both internally and with the help of recognized experts.

    Ready for bigger tasks

    Saturn Oil & Gas has already broadened its management team to be ready for the acquisition of a larger competitor. Wendy Woolsey, who has 25 years of experience in the oil industry, is responsible for finance. Jean-Pierre Colin has been hired as Chief Strategy Advisor. Colin has been considered one of the most important players in the Canadian resource industry for decades. Among other things, he advised several high-ranking politicians in the Canadian federal government and the Privy Council of Canada on Petro-Canada's five acquisitions of the nation's largest oil and gas companies in the 1980s. In addition, the strategist has served on the boards of many successful junior resource companies, including Virginia Gold Inc. which sold its Eleonor project for more than CAD 1 billion to Goldcorp Inc, now known as Newmont Corporation.

    Clear edge

    As to what Colin's goals are, he expressed upon taking office, "Saturn Oil & Gas represents a unique opportunity to build an oil & gas acquisition vehicle that can provide accretive growth and returns for its shareholders and other key stakeholders." At the moment, the stock market value of the Canadian Company is close to EUR 15.0 million. If the expected acquisition goes through, the Company is likely to face a total revaluation.

    Still in boom mode

    Electric cars, and no end in sight. According to analyst Adam Jonas of Morgan Stanley, global sales of electric vehicles are likely to increase by at least 50 percent in 2021 compared to the previous year. The expert also expects growth in vehicles with combustion engines. However, this is only expected to be by a maximum of 5 percent. Jonas cites the further expansion of charging stations on the one hand and the increasing acceptance of e-cars among the population on the other, as reasons. Other reasons include government subsidies and falling prices for vehicles with electric motors. However, the Morgan Stanley analyst sees consolidation in the market, as startups are also fighting for market share alongside car manufacturers. BYD, as an established player, is likely to continue its development. The stock, for example, posted massive gains of more than 10 percent at the start of the week. At the end of yesterday's trading in Europe, BYD was trading at EUR 21.20, not far from its all-time high of EUR 22.39.

    Everything for the subsidiary

    JinkoSolar is doing everything it can to make the IPO of its Jiangxi Jinko subsidiary a success. After last week, five board members announced their immediate resignation at JinkoSolar and defected to the main holding. The Chinese solar module and solar cell producer announced news about the use of the proceeds of the capital increase. JinkoSolar intends to use the net proceeds from the sale of shares to expand production capacity. However, expanding product capacities is currently the main task of Jiangxi Jinko. JinkoSolar still holds just under 74% of the shares and wants to pass on part of the proceeds from the issue, as a loan to the subsidiary.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read